» Articles » PMID: 31126066

Systems Biology Approaches to Investigate Genetic and Epigenetic Molecular Progression Mechanisms for Identifying Gene Expression Signatures in Papillary Thyroid Cancer

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2019 May 26
PMID 31126066
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid cancer is the most common endocrine cancer. Particularly, papillary thyroid cancer (PTC) accounts for the highest proportion of thyroid cancer. Up to now, there are few researches discussing the pathogenesis and progression mechanisms of PTC from the viewpoint of systems biology approaches. In this study, first we constructed the candidate genetic and epigenetic network (GEN) consisting of candidate protein-protein interaction network (PPIN) and candidate gene regulatory network (GRN) by big database mining. Secondly, system identification and system order detection methods were applied to prune candidate GEN via next-generation sequencing (NGS) and DNA methylation profiles to obtain the real GEN. After that, we extracted core GENs from real GENs by the principal network projection (PNP) method. To investigate the pathogenic and progression mechanisms in each stage of PTC, core GEN was denoted in respect of KEGG pathways. Finally, by comparing two successive core signaling pathways of PTC, we not only shed light on the causes of PTC progression, but also identified essential biomarkers with specific gene expression signature. Moreover, based on the identified gene expression signature, we suggested potential candidate drugs to prevent the progression of PTC with querying Connectivity Map (CMap).

Citing Articles

Splicing diversity enhances the molecular classification of pituitary neuroendocrine tumors.

Huang Y, Guo J, Han X, Zhao Y, Li X, Xing P Nat Commun. 2025; 16(1):1552.

PMID: 39934142 PMC: 11814191. DOI: 10.1038/s41467-025-56821-x.


Systems Drug Design for Muscle Invasive Bladder Cancer and Advanced Bladder Cancer by Genome-Wide Microarray Data and Deep Learning Method with Drug Design Specifications.

Su P, Chen B Int J Mol Sci. 2022; 23(22).

PMID: 36430344 PMC: 9692470. DOI: 10.3390/ijms232213869.


GATA binding protein 1 recruits histone deacetylase 2 to the promoter region of nuclear receptor binding protein 2 to affect the tumor microenvironment and malignancy of thyroid carcinoma.

Li M, Jiang H, Chen S, Ma Y Bioengineered. 2022; 13(4):11320-11341.

PMID: 35491849 PMC: 9278442. DOI: 10.1080/21655979.2022.2068921.


Investigating the Role of Obesity in Prostate Cancer and Identifying Biomarkers for Drug Discovery: Systems Biology and Deep Learning Approaches.

Yeh S, Chung Y, Chen B Molecules. 2022; 27(3).

PMID: 35164166 PMC: 8840188. DOI: 10.3390/molecules27030900.


Quantitative prediction model for affinity of drug-target interactions based on molecular vibrations and overall system of ligand-receptor.

Wang X, Cao T, Jia C, Tian X, Wang Y BMC Bioinformatics. 2021; 22(1):497.

PMID: 34649499 PMC: 8515642. DOI: 10.1186/s12859-021-04389-w.


References
1.
Shin M, Kim H, Lee S, Park W, Kim S, Park J . Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res. 2001; 61(13):4942-6. View

2.
Ringel M, Hayre N, Saito J, Saunier B, Schuppert F, Burch H . Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res. 2001; 61(16):6105-11. View

3.
Gupta E, Ito M . Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia. Heart Dis. 2002; 4(2):124-37. DOI: 10.1097/00132580-200203000-00010. View

4.
Stegert M, Tamaskovic R, Bichsel S, Hergovich A, Hemmings B . Regulation of NDR2 protein kinase by multi-site phosphorylation and the S100B calcium-binding protein. J Biol Chem. 2004; 279(22):23806-12. DOI: 10.1074/jbc.M402472200. View

5.
Garcia J, Silva J, Pena C, Garcia V, Rodriguez R, Cruz M . Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer. 2004; 41(2):117-24. DOI: 10.1002/gcc.20062. View